HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

TScan Therapeutics (NASDAQ:TCRX) had its price objective lowered by stock analysts at HC Wainwright from $10.00 to $7.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 488.24% from the stock’s current price.

Other analysts have also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC cut their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Finally, BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, TScan Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $6.60.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $1.19 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $5.56. The firm has a market cap of $67.53 million, a PE ratio of -1.09 and a beta of 1.00. The firm’s fifty day moving average is $1.87 and its 200-day moving average is $1.71.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. Sell-side analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC bought a new stake in TScan Therapeutics during the 1st quarter valued at $49,000. Checkpoint Capital L.P. grew its holdings in shares of TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after buying an additional 261,663 shares during the last quarter. BVF Inc. IL increased its position in shares of TScan Therapeutics by 63.6% during the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after acquiring an additional 1,900,000 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after acquiring an additional 9,676 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of TScan Therapeutics by 149.4% in the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after acquiring an additional 31,481 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.